Nu Skin Enterprises, Inc.

DB:NUS Stock Report

Market Cap: €348.5m

Nu Skin Enterprises Valuation

Is NUS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of NUS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: NUS (€6.95) is trading above our estimate of fair value (€4.77)

Significantly Below Fair Value: NUS is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NUS?

Key metric: As NUS is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for NUS. This is calculated by dividing NUS's market cap by their current revenue.
What is NUS's PS Ratio?
PS Ratio0.2x
SalesUS$1.78b
Market CapUS$362.89m

Price to Sales Ratio vs Peers

How does NUS's PS Ratio compare to its peers?

The above table shows the PS ratio for NUS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average4.1x
BEI Beiersdorf
2.8x5.1%€27.6b
600530 Shanghai Jiaoda OnllyLtd
9xn/aCN¥2.5b
301108 Tongling Jieya Biologic Technology
3.7x23.7%CN¥2.2b
YSG Yatsen Holding
1x5.4%US$448.1m
NUS Nu Skin Enterprises
0.2x-0.06%€362.9m

Price-To-Sales vs Peers: NUS is good value based on its Price-To-Sales Ratio (0.2x) compared to the peer average (4.1x).

Price to Sales Ratio vs Industry

How does NUS's PS Ratio compare vs other companies in the European Personal Products Industry?

8 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.1.4x4.7%
NUS Nu Skin Enterprises
 0.2x-0.06%US$362.89m
NUS 0.2xIndustry Avg. 1.4xNo. of Companies10PS01.63.24.86.48+
8 CompaniesEstimated GrowthMarket Cap
Industry Avg.1.4x8.0%
NUS Nu Skin Enterprises
 0.2x146.5%US$362.89m
No more companies

Price-To-Sales vs Industry: NUS is good value based on its Price-To-Sales Ratio (0.2x) compared to the European Personal Products industry average (1.5x).

Price to Sales Ratio vs Fair Ratio

What is NUS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NUS PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.2x
Fair PS Ratio0.7x

Price-To-Sales vs Fair Ratio: NUS is good value based on its Price-To-Sales Ratio (0.2x) compared to the estimated Fair Price-To-Sales Ratio (0.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst NUS forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€6.95
€7.74
+11.4%
23.6%€10.32€6.34n/a3
Nov ’25€5.60
€8.88
+58.5%
20.9%€10.19€6.25n/a3
Oct ’25€6.50
€10.22
+57.2%
2.1%€10.52€10.06n/a3
Sep ’25€8.30
€10.22
+23.1%
2.1%€10.52€10.06n/a3
Aug ’25€10.30
€11.90
+15.5%
6.6%€12.98€11.13n/a3
Jul ’25€9.70
€11.90
+22.7%
6.6%€12.98€11.13n/a3
Jun ’25€12.00
€11.90
-0.8%
6.6%€12.98€11.13n/a3
May ’25€11.40
€13.55
+18.8%
4.9%€14.48€13.08n/a3
Apr ’25€12.60
€14.39
+14.2%
7.9%€15.78€12.99n/a3
Mar ’25€11.50
€14.39
+25.1%
7.9%€15.78€12.99n/a3
Feb ’25€17.10
€19.19
+12.2%
12.1%€22.84€16.44n/a4
Jan ’25€17.40
€21.30
+22.4%
18.7%€26.86€16.67n/a4
Dec ’24€15.50
€21.51
+38.7%
18.7%€27.12€16.83n/a4
Nov ’24€17.90
€26.39
+47.4%
11.8%€30.43€21.87€5.604
Oct ’24€20.20
€28.14
+39.3%
14.9%€33.11€21.76€6.504
Sep ’24€22.00
€28.79
+30.9%
7.3%€31.99€26.50€8.304
Aug ’24€26.80
€37.75
+40.9%
4.8%€40.33€35.64€10.304
Jul ’24€30.20
€37.75
+25.0%
4.8%€40.33€35.64€9.704
Jun ’24€31.00
€37.75
+21.8%
4.8%€40.33€35.64€12.004
May ’24€35.80
€37.75
+5.4%
4.8%€40.33€35.64€11.404
Apr ’24€34.70
€37.75
+8.8%
4.8%€40.33€35.64€12.604
Mar ’24€37.25
€37.75
+1.3%
4.8%€40.33€35.64€11.504
Feb ’24€38.99
€35.26
-9.6%
5.0%€36.88€32.27€17.104
Jan ’24€39.31
€37.00
-5.9%
7.3%€40.54€33.00€17.404
Dec ’23€39.56
€36.64
-7.4%
9.4%€41.73€33.00€15.504
Nov ’23€38.17
€42.33
+10.9%
5.7%€45.63€39.54€17.904

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

McBride

UK£182.8m

Manufactures and sells private label household and personal care products to retailers and brand owners in the United Kingdom, Germany, France, Italy, Spain, rest of Europe, Asia-Pacific, and internationally.It operates through five segments: Liquids, Powders, Unit dosing, Aerosols, and Asia Pacific.

10W

UK£1.22

7D

7.0%

1Y

82.1%

L'Oréal

€176.0b

Through its subsidiaries, manufactures and sells cosmetic products for women and men worldwide.

LOR

€329.75

7D

1.4%

1Y

-23.3%

Cheerwin Group

HK$2.5b

An investment holding company, manufactures and trades household insecticides and repellents, household cleaning, air care, personal care, pets and pet products, and other products in the People’s Republic of China.

1RQ

HK$0.21

7D

-2.8%

1Y

26.5%